

Effect of Carbamazepine Therapy on Serum Leptin Concentrations

Sandeep Singh'

Department of Biochemistry, College of Colchester, Papua New Guinea

Abstract

During the course of using antiepileptic medication, patients with epilepsy may experience harmful metabolic © 2023 Singh S. This is an open-access article distributed under the

c^¦ { • [~ c@^ C|^æciç^ C [{ { [} • Acc¦iàčci] Li&^} •^, @i&@]^¦ { ic• ` } |^•c|i&c^å

use, distribution, and reproduction in any medium, provided the original author and Garhamazenime: Serum leptin: Antiepileptic drugs and control groups [8, 9, and 10].

Ke d : Garbamazepine: Serum leptin; Antiepileptic drugs

1. d c i

One of the current chemicals involved in the etiopathogenesis of obesity is leptin. Adipocytes produce leptin, and the amount of leptin in circulation is correlated with the mass of adipose tissue. It reduces calorie intake while raising energy usage. It has a lipolytic action and accelerates adipocytes' fatty acid metabolism. It controls fatty acid oxidation rather than storage. Leptin has been shown to have speci c impacts on the immune system, the reproductive system, and even the ability to treat epilepsy due to its actions on the hippocampal neurons. Leptin in uences macrophages and vascular smooth muscle cells, and it also results in the development of atheroma plaques. Leptin interacts with insulin, another key hormone in controlling body weight [1, 2].



None.

C ic. fl.ee.

None.

References

1. Petra K, Sandra B, Miroslav S (2019)

Cl c il

Obesity is one of the metabolic side e ects of antiepileptic drugs, which is a factor that limits treatment. Between 15% and 25% of patients receiving CBZ medication were observed to be obese. e CBZ therapy, has no impact on body weight. Regarding BMI and the obesity ratio in our study, there was no di erence between the patient